Bristol-Myers Squibb Company (BMY) - Stock Analysis
Last updated: Jan 19, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Bristol Myers Squibb (BMY) benefits from 17% Q3 portfolio growth, upcoming FDA review and clinical data catalysts, strong operational turnaround with positive earnings and cash flow, and sustained 17% stock gain over 21 days with technical momentum. Its diversified oncology portfolio and dividend appeal underpin a strong near-term growth case.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong margins ⢠Robust cashflow ⢠Elevated leverage BristolâMyers Squibb has swung from a FY2024 accounting loss to strong core profitability and cash generation in 2025âQ3 (net income $2.2B, Q3 FCF $5.99B, EBITDA margin 34%) but remains heavily levered (debt/equity >4) with large noncash charges that cloud earnings quality.
Price Behavior
Key Price Behavior Insights: ⢠Upward trend ⢠Resistance at $57 ⢠Support $53â$54 Support Level: $53â$54 Resistance Level: $57 Over the last month BMY has trended up from the low-$50s to above $55 with higher highs/lows, meeting resistance near $57 and finding support around $53â$54, suggesting momentum but short-term consolidation after a pullback from the intraday high on 2026-01-14.
Sentiment & News
Key News Insights: ⢠Undervalued valuation ⢠Growth portfolio ⢠Patent/pricing risk BMY is trading as an undervalued, dividend-yielding pharma pivoting to a fast-growing (57% of revenue) late-stage pipeline that offset legacy declines, lifted guidance, and drew institutional buying despite patent and pricing headwinds.
AI Summary
BMY has shifted from a dividendâcentric, legacy pharma income story to a catalystâdriven growthâwithâincome biotech where nearâterm valuation is binary and hinges on upcoming pivotal readouts and successful commercialization of lateâstage assets. Monitor ADEPTâ2/Breyanzi/pumitamig readouts and balanceâsheet metrics (deleveraging pace, refinancing risk) because strong cashflow cushions downside but high debt magnifies downside risk and could force dilution if pipeline setbacks occur.
Description
Bristol-Myers Squibb is a global biopharmaceutical company that researches, develops, licenses, manufactures and markets medicines across oncology, hematology, cardiovascular, immunology, fibrosis, neuroscience and infectious disease. Its commercial portfolio includes oral and biologic therapies for cancer, cardiovascular and immune-mediated conditions, with widely used products such as Eliquis and Opdivo, and it sells through wholesalers, pharmacies, hospitals and government channels. Founded in 1887, the company is headquartered in New York, New York.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 23 | Dec 30 | BMY | Bristol-Myers Squibb Company | Bristol Myers Squibb (BMY) benefits from 17% Q3 portfolio growth, upcoming FDA review and clinical data catalysts, strong operational turnaround with positive earnings and cash flow, and sustained 17% stock gain over 21 days with technical momentum. Its diversified oncology portfolio and dividend appeal underpin a strong near-term growth case. | Closed | -0.1% |
| Dec 4 | Dec 11 | BMY | Bristol-Myers Squibb Company | Bristol Myers Squibb shows compelling near-term upside with strong Q3 revenue and raised guidance, notable clinical/regulatory catalysts (FDA Fast Track, Phase 3 trials), substantial debt reduction, and technical breakout signaling positive momentum. | Closed | -1.4% |